FDA's Selective Response to the IoM Drug Safety Report
This article was originally published in RPM Report
Executive Summary
FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.
You may also be interested in...
Tearing Down Silos at CDER
FDA's memorandum of agreement between drug safety and drug review officials clarifies the processes by which decisions are made on significant safety issues. But one former FDAer thinks that reorganizing the center for drugs is still necessary to ensure a productive approval process.
Help Wanted: FDA Begins Search for New CDER Director
FDA has a lot of hard work ahead to make the new drug safety law a reality. Its first task: find a new director for the Center for Drug Evaluation & Research. That decision might be the most important one the agency makes in determining how the new law works.
Avandia and the Commercial Impact of FDA's Credibility Gap
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.